Evidence map›Paper›PMID 33157292›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.

Wakana Takahashi, Taro Yoneda, Hayato Koba, Tsukasa Ueda, Noriaki Tsuji, Haruhiko Ogawa, Hidesaku Asakura

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. COVID-19 drug discovery and treatment options.Nature reviews. Microbiology · 2024
    Review
  7. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
    Article
  8. Article
  9. Review
  10. A Tale of Two Proteases: MPharmaceuticals (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Wakana TakahashiDepartment of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: wakanakita@gmail.com.
Taro YonedaDepartment of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: taroyoneda@yahoo.co.jp.
Hayato KobaDepartment of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: hayatokoba@gmail.com.
Tsukasa UedaDepartment of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: blacktuna007@gmail.com.
Noriaki TsujiDepartment of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: noriakix1212m@gmail.com.
Haruhiko OgawaDepartment of Environmental and Preventive Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. Electronic address: h-ogawa@jintikai.com.
Hidesaku AsakuraDepartment of Hematology Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. Electronic address: hasakura@staff.kanazawa-u.ac.jp.
Komatsu University · JPKomatsu (Japan) · JPKanazawa University · JPKanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case report describes the clinical course of a patient with COVID-19 pneumonia whose severe hypoxemia, probably caused by DIC and pulmonary embolism, showed remarkable improvement with combination heparin and nafamostat therapy. In addition, beneficial mechanisms of nafamostat against COVID-19 and the necessity of attention to hyperkalemia as an adverse effect are discussed.

Indexed as

AgedAnticoagulantsBenzamidinesBlood CoagulationCOVID-19Disseminated Intravascular CoagulationGuanidinesHumansMaleSARS-CoV-2AnticoagulantsBenzamidinesGuanidinesnafamostatCOVID-19Disseminated intravascular coagulationNafamostatSerine proteinase inhibitor

Identifiers

PMID33157292
PMCPMC7607231
OpenAlexW3097251028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.